Progressive familial intrahepatic cholestasis (PFIC), type 3, is a hereditary disease characterized by impaired bile excretion from the liver, which leads to retention of bile acids in the hepatocyte and, as a result, to liver tissue damage. This disease is autoimmune in nature and most often occurs in children, but can also manifest itself in adulthood. The main mechanism of pathogenesis is the insufficiency of a specific transport mechanism that is responsible for the transport of bile acids across liver cell membranes. This can lead to various clinical manifestations, including pruritus, jaundice, cholestasis and, ultimately, to liver cirrhosis and liver failure.
History of the disease and interesting historical facts
Progressive familial intrahepatic cholestasis, type 3, was first described in the late 20th century, when physicians began to recognize the relationship between genetic abnormalities and liver disease. One of the important steps in the study of this disease was the identification of the role of the ABCB4 gene, which encodes a bile acid transporter. Studies have shown that mutations in this gene lead to impaired bile secretion, which confirmed the hypothesis of the hereditary nature of the disease. Moreover, in recent decades there has been an increase in interest in the study of multigene interactions, which opens up new horizons in understanding the mechanisms of the development of this disease.
Epidemiology
The epidemiology of progressive familial intrahepatic cholestasis type 3 suggests that the disease is rare, but its prevalence is important for diagnosis. According to various estimates, the incidence of PFIC is about 1 in 100,000 newborns. However, given the possibility of latent disease and hidden cases, the actual statistics may be higher. In addition, the disease is more often diagnosed in women, which may be due to certain hormonal factors or mutation characteristics.
Genetic predisposition to this disease
The genetic basis of progressive familial intrahepatic cholestasis type 3 currently involves several key genes, including ABCB4, which encodes a protein that ensures the transport of bile acids. Mutations in this gene can lead to changes in the structure and function of the protein, which in turn disrupts normal bile excretion. Mutations have also been found in the ATP8B1 and Multidrug Resistance Protein 3 (MDR3) genes. The presence of these mutations can lead to the development of cholestasis and an exacerbation of clinical symptoms. Given that the disease is hereditary, the risk of transmission of mutations from parents to children also requires attention in the field of genetic counseling.
Risk factors for the development of this disease
The definition of risk factors for progressive familial intrahepatic cholestasis type 3 includes both genetic and epidemiological aspects. The main risk factors can be divided into several groups:
- Genetic factors: Family history of the disease, mutations in the ABCB4, ATP8B1, MDR3 genes.
- Environmental factors: Exposure to toxic substances such as heavy metals and chemicals.
- Nutrition: Vitamin deficiencies, especially B vitamins, which may play a role in bile acid metabolism.
- Hormonal changes: Pregnancy and hormonal contraceptives can worsen the symptoms of the disease.
- Age: The disease is most often diagnosed in children, but it can manifest itself at a later age.
Diagnosis of this disease
Diagnosis of progressive familial intrahepatic cholestasis, type 3, is based on a comprehensive approach that includes anamnesis, clinical symptoms, as well as laboratory and instrumental studies.
- Main symptoms: Itching, jaundice, dark urine, discolored stool, enlarged liver, fatigue.
- Laboratory tests: Increased levels of bilirubin, aminotransferases, alkaline phosphatase, and absence of bile acids in the urine.
- Radiological examinations: Ultrasound examination of the liver, magnetic resonance cholangiography to assess the condition of the bile ducts.
- Other types of diagnostics: Genetic testing to identify mutations in key genes, liver biopsy to assess the extent of damage.
- Differential diagnosis: Exclusion of other liver diseases such as viral hepatitis and autoimmune diseases.
Treatment
Treatment of progressive familial intrahepatic cholestasis type 3 requires an individual approach and may include several methods:
- General treatment: Diet correction, control over fat and vitamin levels.
- Pharmacological treatment: Taking ursodeoxycholic acid, which helps improve bile secretion and protect liver cells.
- Surgical treatment: In rare cases, surgery may be required, for example on the bile ducts.
- Other types of treatment: Treatment for complications such as liver failure or infectious diseases.
List of medications used to treat this disease
The main medications used to treat progressive familial intrahepatic cholestasis type 3 are:
- Ursodeoxycholic acid (UDCA)
- Cholestyramine
- Corticosteroids (in some cases)
- Medicines aimed at symptomatic therapy (antihistamines for itching)
Disease monitoring
Monitoring of patients with progressive familial intrahepatic cholestasis, type 3, includes regular follow-up examinations that allow evaluation of the effectiveness of therapy and the dynamics of the disease:
- Control stages: Regular liver function tests, blood tests for enzyme levels and bilirubin.
- Forecast: With adequate therapy, it is possible to slow down the progression of the disease, but the risk of complications remains.
- Complications: Liver failure, cirrhosis, choroiditis, pancreatic diseases.
Age-related features of the disease
Progressive familial intrahepatic cholestasis, type 3, Depending on the patient's age, the disease may manifest itself with different symptoms and have different prognostic options. In children, the disease often occurs with more pronounced symptoms of jaundice and itching, while in adults, a latent course with periodic exacerbations may be observed.
Questions and Answers
- What are the main symptoms of progressive familial intrahepatic cholestasis type 3? The main symptoms include itching, jaundice, dark urine, discolored stools and an enlarged liver.
- How is the disease diagnosed? Diagnosis is based on symptoms, laboratory tests, liver ultrasound, and genetic testing.
- What is the treatment for this disease? Treatment includes ursodeoxycholic acid, dietary modifications and, if necessary, surgery.
- What is the prognosis for this disease? The prognosis varies, but with proper treatment, progression can be slowed and the risk of complications reduced.
- What is the risk of disease in adulthood? Adults may experience later onset and increased risk of complications such as cirrhosis and liver failure.
